Evaluation of Anti-SARS-CoV-2 IgA Response in Tears of Vaccinated COVID-19 Subjects
暂无分享,去创建一个
R. De Giorgio | M. D’Accolti | E. Caselli | I. Soffritti | C. Contini | M. Maritati | M. Guarino | F. Bini | C. Gallenga | Eleonora Mazziga
[1] Q. Pan-Hammarström,et al. Mucosal IgA against SARS-CoV-2 Omicron Infection. , 2022, The New England journal of medicine.
[2] A. Angeloni,et al. Evaluation of the Effectiveness of BNT162b2 Primary Vaccination and Booster Dose to SARS-CoV-2 in Eliciting Stable Mucosal Immunity , 2022, Biomedicines.
[3] K. Safranow,et al. IgA-Based Secretory Response in Tears of COVID-19 Patients: A Potential Biomarker of Pro-Inflammatory State in Course of SARS-CoV-2 Infection , 2022, Pathogens.
[4] S. Hober,et al. Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection , 2022, The New England journal of medicine.
[5] V. Simon,et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals , 2022, Nature Communications.
[6] P. Earl,et al. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[7] Yan Liu,et al. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern , 2022, bioRxiv.
[8] J. Sha,et al. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine , 2022, bioRxiv.
[9] I. Weissman,et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection , 2022, Mucosal Immunology.
[10] F. Rey,et al. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2 , 2022, bioRxiv.
[11] S. Karmakar,et al. Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective , 2022, Journal of the Indian Institute of Science.
[12] M. Mni,et al. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections , 2022, Frontiers in Immunology.
[13] A. Casadevall,et al. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence , 2022, Viruses.
[14] R. Chan,et al. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines , 2021, Frontiers in Immunology.
[15] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.
[16] E. van Riet,et al. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection , 2021, bioRxiv.
[17] A. Passaro,et al. Oral Microbiome Dysbiosis Is Associated With Symptoms Severity and Local Immune/Inflammatory Response in COVID-19 Patients: A Cross-Sectional Study , 2021, Frontiers in Microbiology.
[18] Islam Awny,et al. Evaluation of Anti-SARS-CoV-2 IgA in the Conjunctival Secretions of COVID-19 Patients , 2021, Clinical ophthalmology.
[19] D. Diavatopoulos,et al. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection , 2021, Current opinion in infectious diseases.
[20] R. Vieira,et al. In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 Infection , 2021, Frontiers in Immunology.
[21] N. Câmara,et al. SARS-COV-2 and Ocular Surface: From Physiology to Pathology, a Route to Understand Transmission and Disease , 2021, Frontiers in Physiology.
[22] A. Aguzzi,et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19 , 2020, Journal of Allergy and Clinical Immunology.
[23] P. Perri,et al. Anti-SARS-Cov-2 IgA Response in Tears of COVID-19 Patients , 2020, Biology.
[24] S. Zolla-Pazner,et al. Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk , 2020, iScience.
[25] Yiping Wei,et al. Association of Daily Wear of Eyeglasses With Susceptibility to Coronavirus Disease 2019 Infection. , 2020, JAMA ophthalmology.
[26] C. Schiffer,et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction , 2020, Nature Communications.
[27] M. Bhaskar,et al. SARS-CoV-2 Infection Among Community Health Workers in India Before and After Use of Face Shields. , 2020, JAMA.
[28] O. Schwartz,et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.
[29] M. Lako,et al. Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface , 2020, The Ocular Surface.
[30] P. Morgan,et al. The ocular surface, coronaviruses and COVID‐19 , 2020, Clinical & experimental optometry.
[31] E. Duh,et al. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection , 2020, bioRxiv.
[32] M. Krzystolik,et al. The Ocular Manifestations and Transmission of COVID-19: Recommendations for Prevention , 2020, The Journal of Emergency Medicine.
[33] B. Medhi,et al. Ocular Manifestations and Tear or Conjunctival Swab PCR Positivity for 2019-nCoV in Patients with COVID-19: A Systematic Review and Meta-Analysis , 2020, SSRN Electronic Journal.
[34] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[35] P. Secchiero,et al. Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the anti‐tumoral surveillance of the anterior surface of the eye , 2009, Journal of cellular physiology.
[36] A. Saxena. Risk of COVID-19 among Spectacles Wearing Population of Northern India , 2021 .